Does 81518 require prior authorization?

Yes, 81518 requires prior authorization (medium confidence). Conditional coverage; review criteria to confirm PA need.

What is the Medicare reimbursement rate for 81518?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

Prior Auth Required

Conditional coverage; review criteria to confirm PA need (medium confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

The medical record must document that the testing is expected to influence treatment of the condition for which the test is ordered and include an ordering physician/NPP requisition containing the relevant ICD-10-CM diagnosis code.
Ordering physician/NPP documentation should include history and physical or exam findings, problems/diagnoses, and relevant data (e.g., lab tests, imaging) that support medical necessity.
Performing laboratories must retain accreditation, test requisition, test records/procedures, preliminary and final reports, and quality control records and provide them when requested.
For laboratory-developed tests (LDTs)/protocols, documentation must include the diagnostic test/assay, lab/manufacturer, comparable assays (if relevant), assay description, analytical validity, clinical validity, and clinical utility.

When a molecular panel of 5–50 genes is ordered, bill the appropriate panel CPT code (81445, 81449, 81450, or 81451) instead of submitting individual single-gene CPT codes.
When 51 or more genes are ordered for molecular biomarkers, bill the appropriate large-panel CPT code (81455 or 81456) rather than individual gene codes.
When a panel contains more than one but fewer than five genes, use the corresponding existing panel CPT code or CPT 81479 (unlisted molecular pathology procedure) if no specific panel CPT exists.
Use modifier 91 only when a test is performed more than once on the same day for the same patient and the repeat testing is necessary to obtain multiple results in the course of treatment.
Test is covered for postmenopausal women with invasive carcinoma of the breast that is estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) and human epidermal growth factor receptor 2 negative (HER2-).
Test is covered for patients with early-stage disease defined as T1-T3, pathological node status pN0-pN1, and M0 (no distant metastasis).

L37913 — MolDX: Breast Cancer Index (BCI) Gene Expression Test

J05

L36807 — MolDX: Molecular Diagnostic Tests (MDT)

J05

A56335 — Billing and Coding: MolDX: Breast Cancer Index (BCI) Gene Expression Test

J05

A57772 — Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)

J05

Ask Verity about documentation requirements, denial risks, or coverage in your state.